Skip to main content

Genitourinary cancers

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Expert opinion

Bipolar androgen therapy: Progress and future directions

Bipolar androgen therapy: Progress and future directions

Michael Schweizer (University of Washington, Seattle, USA) outlines a new therapy that utilizes both androgen deprivation and administration, which may potentially have benefit for prostate cancer patients.

Expert opinion

Urinary biomarkers in the management of prostate cancer

Urinary biomarkers in the management of prostate cancer

Non-invasive biomarkers have the potential to guide and improve prostate cancer management in many ways. Maria Frantzi, Agnieszka Latosinska, and Harald Mischak (Mosaiques Diagnostics GmbH, Germany) outline some promising markers and what is needed to implement them in the clinic.

medwireNews editor's pick

Equivalent outcomes for robot-assisted and open radical prostatectomy

Surgical robot

Robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy have similar functional outcomes at 2 years, according to phase III study findings in The Lancet Oncology.

medwireNews editor's pick

Germline mutations detected in advanced RCC patients

DNA mutation

Germline mutations may be common in patients with advanced renal cell carcinoma and may have the potential to guide therapy if detected, US researchers report.


Genitourinary cancers coverage at ASCO Annual Meeting 2018

ASCO 2018

14-09-2018 | Screening | News

Meta-analysis consolidates evidence against PSA-based screening

Prostate-specific antigen-based screening may lead to a modest reduction in prostate cancer-specific mortality but has no effect on overall survival, say the authors of a meta-analysis published in The BMJ.


BMJ 2018; 362: k3519, k3702

13-09-2018 | Castration-resistant prostate cancer | News

News in brief

SPARTAN: Adding apalutamide to ADT does not diminish nonmetastatic CRPC HRQoL

Men with high-risk nonmetastatic castration-resistant prostate cancer do not report a deterioration in health-related quality of life when androgen deprivation therapy is supplemented with apalutamide, indicate SPARTAN trial results.

05-09-2018 | FDA | News


PD-L1 diagnostics approved for pembrolizumab, atezolizumab use in urothelial cancer

Read more on this US FDA update here

04-09-2018 | Bladder cancer | News

Neoadjuvant chemotherapy choice impacts bladder cancer outcome

Neoadjuvant chemotherapy with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin achieves better outcomes than gemcitabine plus cisplatin or carboplatin in patients with muscle-invasive bladder cancer, research shows.


JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.3542

04-09-2018 | Castration-resistant prostate cancer | News

Steroid SWITCHing may benefit mCRPC patients who progress on abiraterone

A phase II proof-of-concept study has shown that clinically stable patients with metastatic castration-resistant prostate cancer and limited disease progression during treatment with abiraterone acetate plus prednisone can experience biochemical and radiologic responses following a steroid switch to dexamethasone.


Br J Cancer 2018; doi:10.1038/s41416-018-0123-9

31-08-2018 | Prostate cancer | News

Moderately hypofractionated radiotherapy regimen promising for localized prostate cancer

Intensity-modulated radiation therapy using a moderately hypofractionated, dose-escalated regimen may control localized prostate cancer better than a conventional regimen while shortening treatment duration, a phase III trial suggests.


J Clin Oncol 2018; doi:10.1200/JCO.2018.77.9868

Themed collections

31-05-2018 | Genitourinary cancers | Themed collection | Collection

Best of JCO™ 2018: Genitourinary Cancer Edition

The content compiled here represents some of the most-accessed original research from recently published Journal of Clinical Oncology articles across a range of topics including prostate and bladder cancer. 

Journal articles and book chapters

29-06-2018 | Castration-resistant prostate cancer | Article

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Hussain M et al. N Engl J Med 2018; 378(26): 2465-2474. doi:10.1056/NEJMoa1800536

28-06-2018 | PARP inhibitors | Article

Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

Ashworth A. Lord CJ. Nat Rev Clin Oncol 2018. doi:10.1038/s41571-018-0055-6

14-06-2018 | Renal cell carcinoma | Article

An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma

Grünwald V et al. Nat Rev Urol 2018. doi:10.1038/s41585-018-0034-9.

05-06-2018 | Prostate cancer | Article

Statin use and time to progression in men on active surveillance for prostate cancer

Jayalath VH et al. Prostate Cancer Prostatic Dis 2018. doi:10.1038/s41391-018-0053-x

05-06-2018 | Radiotherapy | Article

Safety of combining radiotherapy with immune-checkpoint inhibition

Hwang WL et al. Nat Rev Clin Oncol 2018. doi: 10.1038/s41571-018-0046-7

04-06-2018 | Renal cell carcinoma | Article

Epigenetics in renal cell cancer: mechanisms and clinical applications

Joosten SC et al. Nat Rev Urol 2018. doi:10.1038/s41585-018-0023-z

27-05-2018 | Prostate cancer | Article

Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms in Predicting Adverse Pathology in Prostate Cancer

Rayn KN et al. J Urol 2018; pii: S0022-5347(18)43271-5. doi:10.1016/j.juro.2018.05.094

Images and illustrations

12-04-2018 | Prostate cancer | Images and illustration slides | Collection

Prostate cancer imaging

This downloadable powerpoint slide set presents an overview of the imaging techniques used to assess prostate cancer from initial diagnosis and staging, to evaluation of residual or recurrent disease after treatment. These slides can be used for reference purposes or for inclusion in one’s own slide sets. Source: Vargas HA et al. Prostate Cancer Imaging. In: Bach Am, Zhang J, eds. Atlas of Genitourinary Oncological Imaging. Springer New York.

image credits